Top Story

Caplacizumab induces rapid response for acquired TTP

February 10, 2016

Caplacizumab induced a faster response time than placebo among patients with acquired thrombotic thrombocytopenic purpura, a rare blood-clotting disorder, according to phase 2 study results published in The New England Journal of Medicine.

However, caplacizumab (Ablynx) — an anti-von Willebrand factor humanized single-variable domain immunoglobulin — also appeared associated with an increased tendency toward bleeding.


VIDEO: Physicians have ‘3 main opportunities’ to reduce colorectal cancer in younger patients

February 10, 2016
As the prevalence of colorectal cancer rises “slowly and steadily” among patients under the age of 50 years, clinicians have three major opportunities to…

Hereditary cancer foundation launches Lynch Syndrome patient registry

February 10, 2016
AliveAndKickn has announced the launch of the HEROIC Registry, a genetic database for people with Lynch Syndrome to share data and further research, according to a press…
In the Journals

Obesity linked to poor outcomes in acute promyelocytic leukemia

February 10, 2016
Obesity appeared significantly associated with shorter DFS and OS among adult patients with acute promyelocytic leukemia, according to a pooled analysis of four clinical…
FDA News

FDA places full clinical hold on pacritinib

February 10, 2016
The FDA has placed a full clinical hold on studies that involve pacritinib, an oral tyrosine kinase inhibitor in development for the treatment of patients with…
More News Headlines »

The Patient with Non-Small Cell Lung Cancer

No commercial support for this activity.

The management of non-small cell lung cancer (NSCLC) has evolved in the past decade, as advances are made in diagnosis…
More »

VIDEO: Increase in cancer among younger patients requires vigilant screening techniques

January 27, 2016
More »

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan morganatic-roan